ANNOUNCING JAPAN’S FIRST NEW HOME TESTING COVID-19 TESTING KITS USING ENHANCED TECHNOLOGY FOR IMPROVED ACCURACY IN ISOLATING FALSE NEGATIVES OF VARIOUS STRAINS
TOKYO, MARCH 1, 2021 – Genesis Healthcare Co., Japan's leading genetic testing and research company announces the publication of its COVID-19 related research by the Journal of Infectious Diseases and Therapy and the expansion of the range of its COVID-19 testing services in Japan.
Committed to providing the highest level of SARS-CoV-2 (COVID-19) testing services in Japan since April 2020, Genesis Healthcare has conducted extensive genetic testing research to ensure safety and testing accuracy that reflects the best interests of the general public, medical community and essential businesses to monitor the spread to the COVID-19 pandemic as different virus strains have been detected.
The research published reflects the rigorous testing accuracy methods undertaken by Genesis Healthcare focusing on designing primers for higher sensitivity and greater accuracy of COVID-19 strains found in Japan and overseas.
As a result of the outcomes of the research, Genesis Healthcare is updating its range of COVID-19 testing services with the introduction of two new GeneLife testing kits from March 1st, 2021.
NEW JAPAN FOCUSED COVID-19 PCR TEST USING A DOUBLE WELL METHOD
Based on findings from extensive research of over 10,000 samples and adhering with the guidelines from NIID (National Institute of Infectious Disease), Genesis Healthcare optimized the primers for the JPN-N2 region and introduces a new commercially available test kit based on RT-PCR testing procedure with a “two well” method to improve sensitivity and isolate detection of false negatives that are especially troublesome to identify in later stage recovering or asymptomatic patients.
The new test is priced at ¥6,980 (inclusive of tax) and is distributed via e-commerce and a range of national retail channels from March 1st, 2021.
UPGRADE OF COVID-19 PCR TEST WITH GLOBAL TESTING PROTOCOLS:
Genesis Healthcare has recently updated its COVID-19 PCR test featuring coverage for global testing protocols such as Japan NIID (JPN-N2), US CDC (N1 and N2) and China CDC (CH-E) enhanced sensitivity to further identify false positives and negatives by redesigning primers specifically designed by in-house development, AI and validation to ensure higher detection of multiple strains found in Japan, Asia and US/Europe (excluding the UK strains at this time). Acknowledged by the medical community as the “international standard” of COVID-19 testing in Japan, Genesis Healthcare strives to continue R&D to upgrade testing protocols to include new strains.
The retail price of this “international standard” test continues to be ¥14,900 (tax included) and is distributed via ecommerce and a range of selected national retail channels.
Through this testing service, Genesis Healthcare collaborates with multiple medical and academic institutions to contribute to on-going research and development to reduce further false negative / false positive identification, updates for new variants such as UK variant with a focus to support further vaccine development as the virus mutates.
The renewed testing service with global testing protocols is distributed via e-commerce and a range of national retail channels from March 1st, 2021 and will be periodically updated to accommodate testing accuracy for new variants.
SAFE, CONVENIENT AND ONE-DAY TURNAROUND
All GeneLife’s COVID-19 testing collection kits feature advanced safety procedures with virus deactivation and stabilization solution to ensure safe transportation and preservation of the virus RNA specimens from the point of collection to testing laboratory facilities. In addition, a UN3373 compliant box is also included as per requirements from Japan Post
Simple and convenient, the testing collection kits from Genesis Healthcare are saliva-based, performed at-home and returned via post.
As part of the service, optional on-line consultation is provided, and the turnaround time is one-day from reception of specimen at the laboratory of Genesis Healthcare.
Genesis Healthcare testing services have been leveraged by individuals, medical institutions and corporations alike. The testing services from Genesis Healthcare have enabled multiple organizations to ensure safe working operating environment as well as business continuity plans in a variety of sectors, such as travel (e.g., cruise companies, embassies…), entertainment (e.g., theaters, events…) as well as multiple medical institutions.
The Journal of Infectious Diseases & Therapy published the research article from Genesis Healthcare under the following citation:
Tsutae W, Chaochaisit W, Aoshima H, Ida C, Miyakawa S, et al. (2021) Detecting and Isolating False Negatives of SARS-Cov-2 Primers and Probe Sets among the Japanese Population: A Laboratory Testing Methodology and Study. J Infect Dis Ther S1:004.
About Genesis Healthcare Co. Ltd
Genesis Healthcare Co., Ltd. is a leading biotech company, pioneering genetic research since 2004 and promoting preventive healthcare and wellness through genetic testing. Leveraging more than 16 years of genetic research and development, Genesis Healthcare empowers medical institutions and end consumers alike to evolve towards personalized wellness and medicine. Originated in Japan, Genesis Healthcare offers medical, corporate, and consumer services through a range of innovative services across the Asia Pacific region.